Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $55.25 | Total: $276.25 |
| 1 | 10 | $46.80 | Total: $468.00 |
| 1 | 25 | $39.65 | Total: $991.25 |
| 1 | 50 | $33.80 | Total: $1,690.00 |
| 1 | 100 | $29.25 | Total: $2,925.00 |
Overview
Pamufetinib (TAS-115) is a potent kinase inhibitor targeting VEGFR and the hepatocyte growth factor receptor (c-MetHGFR), with IC50s of 30 nM for rVEGFR2 and 32 nM for rMET, respectively.
Chemical Properties
| Molecular Formula | C27H23FN4O4S |
| Molecular Weight | 518.56 |
| CAS Numbers | 1190836-34-0 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | O(C=1C2=C(C=C(OC)C(C(NC)=O)=C2)N=CC1)C3=C(F)C=C(NC(NC(CC4=CC=CC=C4)=O)=S)C=C3 |
Storage and Handling
0C Short Term, -20C Long Term
References
Fujita H, et al. The novel VEGF receptorMET-targeted kinase inhibitor TAS-115 has marked in vivo antitumor properties and a favorable tolerability profile. Mol Cancer Ther. 2013 Dec;12[12] 2685-96.